Stockscreener 앱 받기
19.71
1.52%
-0.305
시간 외 거래:
19.98
0.27
+1.37%
전일 마감가:
$20.02
열려 있는:
$20.05
하루 거래량:
760.89K
Relative Volume:
0.89
시가총액:
$1.50B
수익:
$80.89M
순이익/손실:
$-144.73M
주가수익비율:
-7.4098
EPS:
-2.66
순현금흐름:
$-83.87M
1주 성능:
-1.10%
1개월 성능:
+4.62%
6개월 성능:
-9.92%
1년 성능:
+149.49%
1일 변동 폭
$19.41
$20.50
1주일 범위
$19.17
$20.66
52주 변동 폭
$7.83
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
19.71 | 1.50B | 80.89M | -144.73M | -83.87M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
HC Wainwright Brokers Decrease Earnings Estimates for NRIX - MarketBeat
Stifel Nicolaus Boosts Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - MarketBeat
SG Americas Securities LLC Buys 7,141 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Q1 EPS Estimate for Nurix Therapeutics Reduced by Analyst - Defense World
HC Wainwright Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $55,798.35 in Stock - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Gwenn Hansen Sells 3,690 Shares - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Issues Earnings Results - MarketBeat
Stifel Nicolaus Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $36.00 - Defense World
Royal Bank of Canada Raises Nurix Therapeutics (NASDAQ:NRIX) Price Target to $27.00 - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Nurix Therapeutics' SWOT analysis: protein degrader stock's potential By Investing.com - Investing.com Australia
Nurix Therapeutics Faces Financial Risks Amid Supreme Court Regulatory Shift - TipRanks
Nurix Therapeutics Reports Solid Progress and Strong Pipeline - TipRanks
Nurix Therapeutics' SWOT analysis: protein degrader stock's potential - Investing.com India
Stifel raises Nurix stock price target to $36, maintains Buy - MSN
JPMorgan Chase & Co. Has Lowered Expectations for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
Needham & Company LLC Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $28.00 - MarketBeat
8 Analysts Have This To Say About Nurix Therapeutics - Benzinga
RBC Raises Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk - Marketscreener.com
Nurix Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended November 30, 2024 - Marketscreener.com
Nurix Therapeutics Inc. (NRIX) reports earnings - Quartz
Nurix Therapeutics Fiscal Q4 Net Loss Narrows, Revenue Falls -January 28, 2025 at 04:48 pm EST - Marketscreener.com
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
Earnings Flash (NRIX) Nurix Therapeutics Reports Q4 Revenue $13.3M, vs. FactSet Est of $14.6M - Marketscreener.com
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update - GlobeNewswire Inc.
(NRIX) Proactive Strategies - Stock Traders Daily
Nurix Therapeutics Inc (NASDAQ: NRIX): Is It Stable And Growing? - Stocks Register
JPMorgan Chase & Co. Increases Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
JPMorgan Chase & Co. Acquires 31,352 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics appoints new chief commercial officer - MSN
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer - Marketscreener.com
Nurix Therapeutics appoints new chief commercial officer By Investing.com - Investing.com Australia
Nurix Therapeutics Taps Former Ibrutinib Commercial Chief to Lead NX-5948 Launch Strategy - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Receives "Overweight" Rating from Stephens - MarketBeat
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth - Yahoo Finance
Learn to Evaluate (NRIX) using the Charts - Stock Traders Daily
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength? - MSN
Nurix Therapeutics Unveils 2025 Objectives and Achievements - TipRanks
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases - The Manila Times
Nurix's NX-5948 Cancer Drug Achieves 75% Response Rate, Secures Fast Track Status - StockTitan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 7.1%Time to Sell? - MarketBeat
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation (NASDAQ:NRIX) - Seeking Alpha
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%What's Next? - MarketBeat
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Nurix Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
(NRIX) Trading Report - Stock Traders Daily
Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me - Seeking Alpha
Nurix therapeutics chief legal officer sells $112k in stock By Investing.com - Investing.com Nigeria
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):